Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD (NCT05904028)

🧪 Interventions in This Study

• Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule (DRUG)
• Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule (DEVICE)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (64 Sites)

Showing the first 25 of 64 sites.

• Kent W. Small, MD, AMC — Glendale, California
• Loma Linda University — Loma Linda, California
• East Bay Retina Consultants, Inc. — Oakland, California
• Kaiser Permanente - Oakland — Oakland, California
• Southern California Desert Retina Consultants, Inc. — Palm Desert, California
• UC Davis Health Eye Center — Sacramento, California
• Macula Retina Vitreous Institute — Torrance, California
• Bay Area Retina Associates A Medical Group — Walnut Creek, California
• Retina Consultants — Manchester, Connecticut
• National Ophthalmic Research Institute — Fort Myers, Florida
• University of Florida- Jacksonville — Jacksonville, Florida
• Florida Retina Institute, James A. Staman, MD, PA- Jacksonville — Jacksonville, Florida
• Argus Research Center, Inc — Naples, Florida
• Southeast Eye Institute, P.A. dba Eye Associates of Pinellas — Pinellas Park, Florida
• Retina Associates of Sarasota — Sarasota, Florida
• Sarasota Retina Institute — Sarasota, Florida
• Retina Associates of Florida, LLC — Tampa, Florida
• Southeast Retina Center, P.C. — Augusta, Georgia
• Thomas Eye Group — Sandy Springs, Georgia
• Northwestern Memorial Group — Chicago, Illinois
• Rush University Medical Center — Chicago, Illinois
• UIC - Dept of Ophthalmology & Visual Sciences — Chicago, Illinois
• The Trustees of Indiana University — Indianapolis, Indiana
• Midwest Eye Institute — Indianapolis, Indiana
• Wolfe Clinic, P.C.- West Des Moines — West Des Moines, Iowa

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Neovascular Age-related Macular Degeneration

• A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) — Arcadia, California
• A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration — Phoenix, Arizona
• Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) — Beverly Hills, California
• Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration — Gilbert, Arizona
• Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA] — Phoenix, Arizona

Explore by condition: All Neovascular Age-related Macular Degeneration clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.